Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio)

Behavioural Brain Research

Volumn 224, Issue 1, 2011, Pages 135-139

  Seibt, Kelly Juliana ^a   Piato, Angelo Luis ^a   da Luz Oliveira, Renata ^a,b   Capiotti, Katiucia Marques ^a,b   Vianna, Monica Ryff ^a,b   Bonan, Carla Denise ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina INCT TM   (Brazil)

Author keywords

Antipsychotic; Memory; MK 801; Schizophrenia; Zebrafish

Indexed keywords

DIZOCILPINE; HALOPERIDOL; OLANZAPINE; SULPIRIDE;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; MALE; MEMORY CONSOLIDATION; NONHUMAN; PRIORITY JOURNAL; SOCIOPATHY; ZEBRA FISH;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DRUG INTERACTIONS; INTERPERSONAL RELATIONS; MALE; STATISTICS, NONPARAMETRIC; ZEBRAFISH;

EID: 79959573635     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.05.034     Document Type: Article

References (67)

1. Abdul-Monim Z., Reynolds G.P., Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 2006, 169:263-273.
2. Adams B.W., Moghadam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 2001, 50:750-757.
3. Aghajanian G.K., Marek G.J. Serotonin, via 5-HT2A receptors, increases EPSCs in layer v pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999, 825:161-171.
4. Amitai N., Semenova S., Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 2007, 193:521-537.
5. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997, 283:226-234.
6. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 1998, 18:8394-8401.
7. Barbazuk W.B., Korf I., Kadavi C., Heyen J., Tate S., Wun E., et al. The syntenic relationship of the zebrafish and human genomes. Genome Res 2000, 10:1351-1358.
8. Bardgett M.E. Behavioral models of atypical antipsychotic drug action. Atypical antipsychotics: from bench to bedside 2004, 61-93. Marcel Dekker, New York. J.G. Csernansky, J. Laurello (Eds.).
9. Bardgett M.E., Points M., Ramsey-Faulkner C., Topmiller J., Roflow J., McDaniel T., et al. The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss. Neuropsychopharmacology 2008, 33:1980-1991.
10. Becker A., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuro-Psychopharmacol Biol Psychiatry 2004, 28(8):1267-1277.
11. Blank M., Guerim L.D., Cordeiro R.F., Vianna M.R. A one-trial inhibitory avoidance task to zebrafish: rapid acquisition of an NMDA-dependent long-term memory. Neurobiol Learn Mem 2009, 92(4):529-534.
12. Boulay D., Depoortère R., Louis C., Perrault G., Griebel G., Soubrié P. SSR 181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 2004, 46(8):1121-1129.
13. Bubenikova V., Votava M., Horacek J., Palenicek T., Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005, 80:591-596.
14. Bubenikova-Valesova V., Horacek J., Vrajova M., Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008, 32:1014-1023.
15. Crossley N.A., Constante M., McGuire P., Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010, 196(6):434-439.
16. de Moura Linck V., Herrmann A.P., Goerck G.C., Iwu M.M., Okunji C.O., Leal M.B., et al. The putative antipsychotic alstonine reverses social interaction withdrawal in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 2008, 32:1449-1452.
17. Didriksen M., Skarsfeldt T., Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 2007, 193:225-233.
18. Dodd A., Curtis P.M., Williams L.C., Love D.A. Zebrafish: bridging the gap between development and disease. Hum Mol Genet 2000, 9(16):2443-2449.
19. Egan R.J., Bergner C.L., Hart P.C., Cachat J.M., Canavello P.R., Elegante M.F., et al. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav Brain Res 2009, 205(1):38-44.
20. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 2000, 11(3-4):223-233.
21. Evins A.E., Amico E.T., Shih V., Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 1997, 104:761-766.
22. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci 2003, 1003:119-130.
23. Gerlai R., Lahav M., Guo S., Rosental A. Drinks like a fish: zebrafish (Danio rerio) as a behavior genetic model to study alcohol effects. Pharmacol Biochem Behav 2000, 67(4):773-782.
24. Gerlai R. Zebra fish: an uncharted behavior genetic model. Behav Genet 2003, 33(5):461-468.
25. Giacomini N.J., Rose B., Kobayashi K., Guo S. Antipsychotics produce locomotor impairment in larval zebrafish. Neurotoxicol Teratol 2006, 28:245-250.
26. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001, 158:1367-1377.
27. Goldberg T.E., Gold J.M. Neurocognitive deficits in schizophrenia 1995, Blackwell, London, UK.
28. Gray L., van den Buuse M., Scarr E., Dean B., Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 2009, 12(1):45-60.
29. Grossman L., Stewart A., Gaikwad S., Utterback E., Wu N., Dileo J., et al. Effects of piracetam on behavior and learning in adult zebrafish. Brain Res Bull 2011, 85(1-2):58-63.
30. Guo S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafishŽ. Genes Brain Behav 2004, 3:63-74.
31. Guo S. Using zebrafish to assess the impact of drugs on neural development and function. Expert Opin Drug Discov 2009, 4(7):715-726.
32. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1113-1123.
33. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 1998, 351:163-171.
34. Ivetac I., Becanovic J., Krishnapillai V. Zebrafish: genetic tools and genomics. Asia-Pac J Mol Biol Biotechnol 2000, 8:1-11.
35. Jacobs P.S., Taylor B.M., Bardgett M.E. Maturation of locomotor and Fos responses to NMDA antagonists, PCP and MK-801. Dev Brain Res 2000, 122:91-95.
36. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9:984-997.
37. Jones D.N.C., Gartlon J.E., Minassian A., Perry W., Geyer M. Developing new drugs for schizophrenia: from animals to the clinic. Animal and translational models for CNS drug discovery. Psychiatric disorders 2008, vol. 1:199-261. Elsevier, New York.
38. Kapur S., Zipursky R., Jones C., et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
39. Kari G., Rodeck U., Dicker A.P. Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther 2007, 82:70-80.
40. Kiang M., Daskalakis Z.J., Christensen B.K., Remington G., Kapur S. Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. J Psychiatry Neurosci 2003, 28:293-299.
41. Kokel D., Peterson R.T. Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish. Brief Funct Genomic Proteomic 2008, 7(6):483-490.
42. Kristiansen L.V., Huerta I., Beneyto M., Meador-Woodruff J.H. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007, 7:48-55.
43. Large C.H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugsŽ. J Psychopharmacol 2007, 21:283-301.
44. Levin E.D., Petro A., Caldwell D.P. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(4):581-586.
45. Levin E.D., Bencan Z., Cerutti D.T. Anxiolytic effects of nicotine in zebrafish. Physiol Behav 2007, 90(1):54-58.
46. Li J.T., Su Y.A., Guo C.M., Feng Y., Yang Y., Huang R.H., et al. Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats. Eur J Pharmacol 2011, 652(1-3):65-72.
47. McClelland G.R., Cooper S.M., Pilgrim A.J. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 1990, 30:795-803.
48. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathways from NMDA receptor-blocked to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 7:921-927.
49. Nilsson M., Waters S., Waters N., Carlsson A., Carlsson M.L. A behavioural pattern analysis of hypoglutamatergic mice - effects of four different antipsychotic agents. J Neural Transm 2001, 108:1181-1196.
50. Ninan I., Jardemark K.E., Wang R.Y. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-d-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 2003, 44:462-472.
51. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004, 72:29-39.
52. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiat Res 1999, 33:523-533.
53. Parikh V., Terry A.V., Khan M.M., Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Influence of long-lasting administration of neuroleptics on cortical NMDA. Psychopharmacology (Berl) 2004, 172:365-374.
54. Pearlson G.D. Neurobiology of schizophrenia. Ann Neurol 2000, 48:556-566.
55. Porsolt R.D., Moser P.C., Castagne V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 2010, 333(3):632-638.
56. Rihel J., Prober D.A., Arvanites A., Lam K., Zimmerman S., Jang S., et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 2010, 327(5963):348-351.
57. Rung J.P., Carlsson A., Ryden M.K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats, a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:827-832.
58. Seibt K.J., Oliveira Rda L., Zimmermann F.F., Capiotti K.M., Bogo M.R., Ghisleni G., et al. Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio). Behav Brain Res 2010, 214(2):417-422.
59. Sison M., Gerlai R. Behavioral performance altering effects of MK-801 in zebrafish (Danio rerio). Behav Brain Res. 2011, 220(2):331-337.
60. Snighda S., Neill J.C. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats-a preliminary investigation. Behav Brain Res 2008, 187:489-494.
61. Stuchlík A., Petrásek T., Vales K. Effect of alpha(1)-adrenergic antagonist prazosin on behavioral alterations induced by MK-801 in a spatial memory task in Long-Evans rats. Physiol Res 2009, 58:733-740.
62. Su Y.A., Si T.M., Zhou D.F., Guo C.M., Wang X.D., Yang Y., et al. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. Eur J Pharmacol 2007, 564:123-130.
63. Swain H.A., Sigstad C., Scalzo F.M. Effects of dizocilpine (MK-801) on circling behavior, swimming activity, and place preference in zebrafish (Danio rerio). Neurotoxicol Teratol 2004, 26:725-729.
64. Tsang M., Zebrafish: A tool for chemical screens. Birth Defects Res C Embryo Today 2010, 90(3):185-192. [Review].
65. Wong A.H., Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003, 27:269-306.
66. Wullimann M.F., Mueller T. Teleostean and mammalian forebrains contrasted: evidence from genes to behavior. J Comp Neurol 2004, 475:143-162.
67. Zajaczkowski W., Czyrak A., Wedzony K. A competitive antagonist of NMDA receptors CGP 40116 attenuates experimental symptoms of schizophrenia evoked by MK-801. Pol J Pharmacol 2003, 55:703-711.